Pharmacogenomics of Oxidative Stress-Related Genes in Lymphoma
N/A
N/A
Both
Lymphoma
Trial Information
Pharmacogenomics of Oxidative Stress-Related Genes in Lymphoma
OBJECTIVES:
- To determine if toxicity following treatment for lymphoma varies according to genetic
polymorphisms in oxidative stress-related genes (i.e., SOD2, CAT, GPX1, GSTM1, and
GSTP1).
- To assess whether these genetic polymorphisms are associated with progression-free
survival and/or overall survival in these patients treated for lymphoma.
OUTLINE: Previously collected samples are used for biomarker analysis.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of aggressive B-cell non-Hodgkin lymphoma
- Previously treated with curative intent using anthracycline-based therapies
- Previously collected paraffin-embedded diagnostic tissues from clinical trials that
were collected as part of SWOG treatment protocols (S8516, S8736, S9125, S9240, and
S9349) available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Association of polymorphisms in oxidative stress-related genes with overall survival and/or progression-free survival
Safety Issue:
No
Principal Investigator
Margaret M. Briehl, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
University of Arizona
Authority:
Unspecified
Study ID:
CDR0000643248
NCT ID:
NCT00985699
Start Date:
April 2009
Completion Date:
Related Keywords:
- Lymphoma
- non-Hodgkin lymphoma
- cutaneous B-cell non-Hodgkin lymphoma
- extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
- nodal marginal zone B-cell lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
Name | Location |
|---|
